Research programme: antibacterials/antifungals - Diversa/IntraBiotics
Alternative Names: Antibacterials/antifungals research programme - Diversa/IntraBioticsLatest Information Update: 11 Nov 2002
At a glance
- Originator Ardea Biosciences; Diversa
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Mycoses
Most Recent Events
- 11 Nov 2002 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 11 Nov 2002 Discontinued - Preclinical for Mycoses in USA (unspecified route)
- 15 Jan 2001 Preclinical development for Bacterial infections in USA (Unknown route)